Table 2.
MIC values (µg/mL) for MDR strains (n = 9).
| Antibiotics Classes |
Antibiotics | Strains | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ID. 17 | ID. 36 | ID. 49 | ID. 50 | ID. 51 | ID. 52 | ID. 53 | ID. 57 | ID. 58 | ||
| Aminoglycosides | GEN | ≥8 | ≤0.5 | ≤0.5 | ≥1 | ≤0.5 | ≤0.5 | ≥1 | ≤0.5 | ≤0.5 |
| Beta lactams | AMP | ≥64 | >64 | >64 | >64 | >64 | >64 | ≥4 | ≤1 | ≥2 |
| TAZ | ≥0.5 | ≤0.5 | ≤0.5 | ≥4 | ≥4 | ≥4 | ≤0.5 | ≤0.5 | ≥1 | |
| FOT | ≤0.25 | ≤0.25 | ≤0.25 | >4 | >4 | >4 | ≤0.25 | ≤0.25 | ≥0.5 | |
| MERO | ≤0.03 | ≤0.03 | ≤0.03 | ≤0.03 | ≤0.03 | ≤0.03 | ≤0.03 | ≤0.03 | ≤0.03 | |
| Phenicoles | CHL | ≤8 | ≥16 | ≤8 | ≤8 | ≤8 | ≥16 | ≤8 | ≤8 | ≤8 |
| Polymixine | COL | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 | ≤1 | ≥4 | ≤1 | ≤1 |
| Quinolones | NAL | ≥8 | >128 | ≥16 | >128 | >128 | >128 | >128 | >128 | >128 |
| CIP | ≥0.03 | ≥0.25 | ≥0.5 | ≥0.12 | ≥0.25 | ≥0.25 | ≥0.5 | ≥1 | ≥0.25 | |
| Sulfonamides | SMX | ≥64 | >1024 | >1024 | >1024 | >1024 | >1024 | >1024 | >1024 | >1024 |
| TMP | ≤0.25 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | >32 | |
| Tetracyclines | TET | >64 | >64 | >64 | ≥64 | >64 | >64 | >64 | >64 | >64 |
| TGC | ≥1 | ≥2 | ≥2 | ≥1 | ≥1 | ≥2 | ≥1 | ≥2 | ≥1 | |
| Macrolides | AZI | ≥8 | ≥8 | ≥8 | ≥16 | ≥4 | ≥4 | ≥16 | ≥8 | ≥8 |
Gentamicin (GEN, 0.5–32 µg/mL); ampicillin (AMP, 1–64 µg/mL); ceftazidime (TAZ, 0.5–8 µg/mL); cefotaxime (FOT, 0.25–4 µg/mL); meropenem (MERO, 0.03–16 µg/mL); chloramphenicol (CHL, 8–128 µg/mL); colistin (COL, 1–16 µg/mL); nalidixic acid (NAL, 4–128 µg/mL); ciprofloxacin (CIP, 0.015–8 µg/mL); sulfamethoxazole (SMX, 8–1024 µg/mL); trimethoprim (TMP, 0. 25–32 µg/mL); tetracycline (TET, 2–64 µg/mL); tigecycline (TGC, 0.25–8 µg/mL); azithromycin (AZI, 2–64 µg/mL); resistances are represented in bold.